Synlogic, Inc. (NASDAQ:SYBX) Short Interest Down 30.9% in December

Synlogic, Inc. (NASDAQ:SYBX) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 61,000 shares, a decrease of 30.9% from the December 15th total of 88,300 shares. Based on an average daily volume of 33,100 shares, the short-interest ratio is currently 1.8 days. Currently, 0.9% of the company’s stock are sold short.

Synlogic Stock Down 0.7 %

Shares of Synlogic stock traded down $0.01 during midday trading on Thursday, hitting $1.45. The company had a trading volume of 13,981 shares, compared to its average volume of 22,398. The company has a fifty day simple moving average of $1.42 and a 200 day simple moving average of $1.47. The stock has a market cap of $16.97 million, a price-to-earnings ratio of -0.35 and a beta of 0.80. Synlogic has a 12-month low of $1.22 and a 12-month high of $3.73.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.17. As a group, analysts expect that Synlogic will post -2.71 EPS for the current year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.